In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries

Simple item page
dc.contributor.authorAppel, Tobias Manuel
dc.contributor.authorMojica, María Fernanda
dc.contributor.authorCadena, Elsa De La
dc.contributor.authorPallares, Christian José
dc.contributor.authorRadice, Marcela A.
dc.contributor.authorCastañeda-Méndez, Paulo
dc.contributor.authorJaime-Villalón, Diego A.
dc.contributor.authorGales, Ana C.
dc.contributor.authorMunita, José
dc.contributor.authorVillegas, María Virginia
dc.date.accessioned2021-08-16T14:57:48Z
dc.date.available2021-08-16T14:57:48Z
dc.date.issued2020
dc.description.abstractBackground: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which has shown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America.es
dc.identifier.citationAntibiotics, 2020, vol. 9, 62es
dc.identifier.urihttps://doi.org/10.3390/antibiotics9020062es
dc.identifier.urihttp://hdl.handle.net/11447/4312
dc.language.isoenes
dc.subjectAntimicrobial activityes
dc.subjectArgentinaes
dc.subjectBraziles
dc.subjectChilees
dc.subjectColombiaes
dc.subjectMéxicoes
dc.titleIn Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countrieses
dc.typeArticlees

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
In Vitro Susceptibility to CeftazidimeAvibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries.pdf
Size:
223.68 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services